News | January 26, 2021
Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
We now rank 3rd in pharmaceutical production by volume and 14th by value
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
